AMA Journal of Ethics®

Illuminating the art of medicine

Journal of Ethics Header

AMA Journal of Ethics®

Illuminating the art of medicine

Virtual Mentor. October 2014, Volume 16, Number 10: 813-817.

State of the Art and Science

  • Print
  • |
  • View PDF

I, Robotic Surgeon

The use of robots in surgery raises ethical questions regarding training, reporting standards, and financial conflicts of interest.

Monique A. Spillman, MD, PhD, and Robert M. Sade, MD

When Isaac Asimov penned his famous novel, I, Robot [1], he presented the world with three Laws of Robotics. His laws were intended for human interactions with fictional autonomous robots. We can apply the laws to our understanding of the current surgeon interface with robotic surgical systems if we acknowledge that the autonomy resides in the surgeon. The new technology gets the attention, but robotic surgery still remains a human endeavor of medical practice and should be subject to the same principles of medical education and ethics as any other method of surgery. In this paper, we will apply the concepts of the Three Laws to explore ethical questions surrounding the education of resident physicians in robotic surgery, appropriate responses of trainees to robot system failures, and the financial conflicts of interest facing residents who become robotic surgeons.

First Law: A Robot Must Not Harm a Patient

The First Law of Robotics states that “A robot may not injure a human being or, through inaction, allow a human being to come to harm.” Applying this law with the surgeon as seat of the robot’s autonomous will accords with the ethical principle of nonmaleficence that requires that physicians’ actions not intentionally cause harm. The two questions for the training of new surgeons, then, are can training in robotic surgery hurt patients and can lack of training in robotic surgery, “through inaction, allow a human being to come to harm” [1]? The argument has been made that training in robotic hysterectomy is hampering the development of residents’ skills in traditional techniques [2] and may therefore be contributing to producing newly minted surgeons who are underprepared for practice. In this sense, the training could be said to harm patients.

What about nonuse of robotic surgery allowing “a human to come to harm”? If one views the robot as simply another tool in the surgeon’s armamentarium, one that is neither better nor worse than the tools of traditional laparoscopy or laparotomy, then omitting robotic training from graduate medical education is ethically neutral. If one views robotic surgery as a major advance that allows more patients to have complex minimally invasive surgeries with shorter recovery times, however, then omission of robotic surgical training would in fact, be harmful to the population of patients that the trainee would serve in the future.

An important caveat in attempting to answer both questions is the metaethical principle that good ethics begins with good facts. The facts that could help answer the ethical questions related to dedicated training time for robotic versus laparoscopic and open techniques of hysterectomy are not available, so these questions remain open.

Second Law: Robot Malfunctions Must Be Reported

Asimov’s Second Law of Robotics is: “A robot must obey the orders given to it by human beings, except where such orders would conflict with the First Law” [1]. The Engineering and Physical Sciences Research Council translates this succinctly as, “Robots are products. They should be designed using processes which assure their safety and security” [3].

Surgical tools have become increasingly more complex and prone to failure. This is certainly the case with complex robotic surgery systems, which contain multiple components. Communication among the patient docking arms, camera, and surgeon console are critical for the success of the operation, as well as patient safety, and failure of the system at any of these critical nodes could cause harm to the patient. The responsibility for preventing that harm resides with the surgeon who is using the robot. He or she must report a malfunction of the robotic equipment to the manufacturer, hospital risk management, and, for serious adverse events, the Food and Drug Administration (FDA). Failure to do so is a lapse of the surgeon’s ethical duty [4]. This duty is particularly important in light of the FDA’s recent warning letter to Intuitive Surgical, Inc., manufacturers of a robotic system, criticizing the company for delaying reports of technical issues that could have resulted in patient harm [5].

Third Law: Promotion of Robots Leads to Conflicts of Interest

The Third Law of Robotics is: “A robot must protect its own existence” as long as doing so does not interfere with the first two laws. Robotic surgery has become big business for both the manufacturers and the hospitals that have invested in the multimillion-dollar equipment [6]. The third law implies that the autonomous robot—in our case, the autonomous robot-using surgeon—protect the existence and promote the use of robotic surgery. Trainees in robotic surgery, however, must be aware of the intense financial pressures to use the technology, and they must be cognizant of a critically important distinction: the primary ethical obligation of a physician is to the patient, while the primary fiduciary duty of the company is to its stockholders. This difference presents a significant danger—co-optation by hospital administrators or industry representatives that may result in treatment choices that do not primarily benefit the patient. Surgeons might be co-opted in a couple of ways.

Advertising. Hospitals may invest heavily in advertising of robotic surgery and anticipate that their surgeons will participate in the advertising. For gynecologic surgery, advertising images (64.1 percent) and text (24 percent) are often provided directly by the manufacturer of the system [7]. Newly minted surgeons should be aware of how their credentials are used in advertising and ensure that any such advertising is accurate. Some surgical specialty organizations hold surgeons responsible for the truth and accuracy of all advertising related to their programs, regardless of whether they were consulted before publication of the advertising material. For example, the American College of Obstetricians and Gynecologists Committee on Ethics states, “In considering appropriate marketing practices, physicians should evaluate not only their own actions but also those undertaken on their behalf by hospitals or other health care centers that may be marketing their services” [8]. Claims of superiority of the robotic procedure, one surgeon, or one surgical center over another must be backed up by objective data. In the absence of such data, claims of superiority may not only fail the sniff test, but may be considered untruthful, misleading, or deceptive [9] and thereby unethical and possibly illegal. An important and highly relevant problem is that few high-quality data (such as randomized controlled trials) have compared robotic surgery with other methods, so the range of accurate marketing claims is limited [6].

Costs. Hospitals that have made large capital investments in robotic systems are pushing surgeons to have the robots in use daily to increase the return on the hospitals’ investment, as recommended in the memorandum to hospital executives from Intuitive Surgical [10]. The cost of robotic procedures is considerably higher than that of comparable procedures performed by laparoscopy (although the cost differential decreases somewhat with an increasing volume of robotically performed surgeries) [6, 11]. Switching surgeries to the robotic platform is certainly a “high-cost” conversion, and, again, reliable and consistent data that robotic hysterectomy presents higher quality or better outcomes are lacking [12]. In the current health care reform environment, cost and quality are garnering more attention than ever before. By shifting resident teaching time from standard laparoscopy to robotic surgery, we may be producing “high-cost” surgeons who will be penalized by insurers, whether or not the cost is justified by better outcomes.


So is robotic surgery training in residency a good thing or a bad thing? Only time, experience, and reliable data will tell. The market forces driving this technology today may be completely different in 10 years. However, the timeless ethical and educational principles in surgical training will outlast the popular technology of today as well as the next surgical fad. As always, the paramount consideration must be the safety of the patient, rather than the exact tools utilized for the surgery.


  1. Isaac A. I, Robot. New York, NY: Bantam Dell; 1991.
  2. Parker MA, Digiacomo T, Shepherd K, Gardner MO, Doyle NM. Robotic surgery: resident friend or foe? Obstet Gynecol. 2014;123 Suppl 1:118s.
  3. Engineering and Physical Sciences Research Council. Principles of robotics: regulating robots in the real world. ourportfolio/themes/engineering/ activities/principlesofrobotics/. Accessed August 24, 2014.
  4. American Medical Association. Opinion 9.032 - Reporting adverse drug or device events. Code of Medical Ethics. physician-resources/medical-ethics/ code-medical-ethics/ Accessed August 24, 2014.
  5. Kage EA. Intuitive Surgical, Inc. warning letter. US Food and Drug Administration; 2013. EnforcementActions/WarningLetters/ 2013/ucm363260.htm. Accessed August 25, 2014.
  6. Barbash GI, Glied SA. New technology and health care costs—the case of robot-assisted surgery. New Engl J Med. 2010;363(8):701-704.
  7. Schiavone MB, Kuo EC, Naumann RW, et al. The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals. Am J Obstet Gynecol. 2012;207:174.e1-7.
  8. American College of Obstetricians and Gynecologists Committee on Ethics. Committee Opinion 510: ethical ways for physicians to market a practice. Committee-Opinions/Committee-on-Ethics/ Ethical-Ways-for-Physicians-to-Market-a-Practice. Accessed July 8, 2014.
  9. American College of Obstetricians and Gynecologists. Code of Professional Ethics. Washington DC: American College of Obstetricians and Gynecologists; 2011. National%20Officer%20Nominations%20Process/ACOGcode.pdf. Accessed August 24, 2014.
  10. Barry K. Planning for long-term success with a robotic surgery program. Intuitive Surgical. Accessed August 24, 2014.
  11. Wright JD, Ananth CV, Tergas AI, et al. An economic analysis of robotically assisted hysterectomy. Obstet Gynecol. 2014;123(5):1038-1048.
  12. Sarlos D, Kots LA. Robotic versus laparoscopic hysterectomy: a review of recent comparative studies. Curr Opin Obstet Gynecol. 2011;23(4):283-288.

Monique A. Spillman, MD, PhD, practices gynecologic oncology with Texas Oncology at the Baylor Charles A. Sammons Cancer Center in Dallas, Texas, and is a member of the American Medical Association Council on Ethical and Judicial Affairs. She was previously an associate professor of obstetrics and gynecology at the University of Colorado and chair of the ethics committee of the American College of Obstetricians and Gynecologists.

Robert M. Sade, MD, is distinguished university professor, professor of surgery and head of the bioethics section in the Division of Cardiothoracic Surgery, director of the Institute of Human Values in Health Care, and director of the clinical research ethics program of the South Carolina Clinical and Translational Research Institute, all at the Medical University of South Carolina in Charleston. He is chair of the Ethics Committee of the American Association for Thoracic Surgery and of the Cardiothoracic Ethics Forum. Previously he was chair of the American Medical Association Council on Ethical and Judicial Affairs.


Dr. Spillman has participated in the Intuitive Surgical, Inc. initial robotic surgery training course online and in person, and performs robotic surgery in her practice of gynecologic oncology. She also taught robotic surgery to gynecologic oncology fellows and residents at the University of Colorado.

When the Evidence Isn’t There—Seeking Informed Consent for New Procedures, January 2011


The ideas expressed in this work do not represent the views of Texas Oncology or Baylor University Medical Center. Dr. Spillman is currently a member of the AMA Council on Ethical and Judicial Affairs but this work represents her own views, not the policy of the AMA or the American Congress of Obstetricians and Gynecologists, and was commissioned prior to her appointment to the Council.

The viewpoints expressed on this site are those of the authors and do not necessarily reflect the views and policies of the AMA.